[go: up one dir, main page]

ATE209909T1 - Verwendung von tachykinin-antagonisten zur behandlung von erbrechen - Google Patents

Verwendung von tachykinin-antagonisten zur behandlung von erbrechen

Info

Publication number
ATE209909T1
ATE209909T1 AT94200691T AT94200691T ATE209909T1 AT E209909 T1 ATE209909 T1 AT E209909T1 AT 94200691 T AT94200691 T AT 94200691T AT 94200691 T AT94200691 T AT 94200691T AT E209909 T1 ATE209909 T1 AT E209909T1
Authority
AT
Austria
Prior art keywords
tachykinin antagonists
antagonists
treat vomiting
vomiting
treat
Prior art date
Application number
AT94200691T
Other languages
English (en)
Inventor
Russell Michael Hagan
Keith Thomas Bunce
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE209909T1 publication Critical patent/ATE209909T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT94200691T 1993-03-19 1994-03-17 Verwendung von tachykinin-antagonisten zur behandlung von erbrechen ATE209909T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305718A GB9305718D0 (en) 1993-03-19 1993-03-19 Medicaments

Publications (1)

Publication Number Publication Date
ATE209909T1 true ATE209909T1 (de) 2001-12-15

Family

ID=10732372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94200691T ATE209909T1 (de) 1993-03-19 1994-03-17 Verwendung von tachykinin-antagonisten zur behandlung von erbrechen

Country Status (9)

Country Link
US (2) US5547964A (de)
EP (1) EP0615751B1 (de)
JP (2) JPH072658A (de)
AT (1) ATE209909T1 (de)
DE (1) DE69429299T2 (de)
DK (1) DK0615751T3 (de)
ES (1) ES2164684T3 (de)
GB (1) GB9305718D0 (de)
PT (1) PT615751E (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195867T1 (de) * 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994027966A1 (en) * 1993-05-28 1994-12-08 Pfizer Inc. Process for preparing and resolving 2-phenyl-3-aminopiperidine
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
DK0780375T3 (da) * 1995-12-21 2002-10-07 Pfizer 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
WO1997049393A1 (en) * 1996-06-26 1997-12-31 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
AU1409100A (en) * 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP1205855A3 (de) * 2000-11-10 2006-01-25 Masae Yanagi Verfahren, System und Vorrichtung zum Verwalten von Daten, Datenhandlungsgerät, Rechnerprogramm und Speichermedium
CA2567342A1 (en) * 2004-06-08 2005-12-22 Travis T. Wager Aza-bicyclo[3.1.0]hex-1-yl derivatives active as nk1 antagonists
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
KR101834577B1 (ko) * 2009-08-14 2018-03-05 옵코 헬스, 인크. 뉴로키닌-1 길항제의 정맥내 제형
MX385788B (es) 2015-03-04 2025-03-18 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant.
WO2020019247A1 (en) * 2018-07-26 2020-01-30 Xw Laboratories, Inc. Compounds as neurokinin-1 receptor antagonists and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
FR2610323B1 (fr) * 1987-02-04 1989-06-23 Delalande Sa Enantiomeres de configuration absolue s de derives amide de l'amino-3 quinuclidine, leur procede de preparation et leur application en therapeutique
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
SK284185B6 (sk) * 1991-03-26 2004-10-05 Pfizer Inc. Spôsob prípravy substituovaných piperidínov
UA39168C2 (uk) * 1991-06-20 2001-06-15 Пфайзер, Інк. Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
EP0593557B1 (de) * 1991-07-05 1996-01-31 MERCK SHARP & DOHME LTD. Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
ATE195867T1 (de) * 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
DK0615751T3 (da) 2002-02-18
US6329394B1 (en) 2001-12-11
EP0615751B1 (de) 2001-12-05
EP0615751A1 (de) 1994-09-21
DE69429299T2 (de) 2002-10-17
PT615751E (pt) 2002-04-29
ES2164684T3 (es) 2002-03-01
US5547964A (en) 1996-08-20
DE69429299D1 (de) 2002-01-17
GB9305718D0 (en) 1993-05-05
JP2000191522A (ja) 2000-07-11
JPH072658A (ja) 1995-01-06

Similar Documents

Publication Publication Date Title
ATE209909T1 (de) Verwendung von tachykinin-antagonisten zur behandlung von erbrechen
ATE209490T1 (de) Substanz p antagonisten zur behandlung von erbrechen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE59601880D1 (de) Verfahren zur herstellung hydrophiler oder teilweise hydrophiler, anorganischer aerogele
ATE206757T1 (de) Thrombin sowie verfahren zu seiner herstellung
ATE319823T1 (de) Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ES2058346T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
DE69735482D1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE3851584D1 (de) Gegen Allergie wirkende Benzothiophene und neue und andere ausgewählte Benzothiophene, beide mit Wirkung zur Behandlung von akuten Atmungsangstanzeichen.
ES2072975T3 (es) Mezcla de esterilizante y metodo de esterilizacion.
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69004924D1 (de) Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
SE9301606D0 (sv) Composition for the treatment of impaired hair growth
DE59407576D1 (de) Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0615751

Country of ref document: EP